AccuStem pursuing strategic commercialization plan intending to launch the MSC test in the US in 2026 LONDON and PHOENIX, Ariz., March 18, 2025 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB: ACUT ...
AccuStem Sciences, Inc. (OTCQB: ACUT ), a clinical stage diagnostics company dedicated to improving outcomes for patients with or at risk of cancer, today announced an expansion of its blood-based ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback